Abstract
Background: Based on historical data on the role of radioimmunotherapy (RIT) in pretreated non-Hodgkin lymphoma, we reviewed our hospital's clinical database. Patients and Methods: Between 2005 and 2008, 57 patients previously treated with at least 1 rituximab-containing chemotherapy were treated with Yttrium-90-labeled ibritumomab tiuxetan (90Y-IT). The median number of pretreatments was 3 (range, 1-9 pretreatments). A total of 46 patients had stage III/IV disease (31 with bone marrow involvement); 6 had bulky disease. According to histology, 53 were follicular lymphoma (FL), 2 were marginal zone lymphoma, and 2 were small lymphocytic lymphoma. Results: Overall response rate was 93% (53 of 57); complete response (CR) rate was 70% (40 of 57). Twenty-six of 40 patients (65%) who obtained a CR are in continuous CR (CCR) with a median follow-up of 20 months (range, 10-42 months); 4 of them still maintain their CCR after 36 months. All patients achieving a CCR had FL, and 21 of them with stage III/IV disease; 12 of 26 had been heavily pretreated (≥ 3 previous treatments), and 2 had had autologous stem cell transplantation. Toxicity was primarily hematologic and mostly transient; no grade 4 extrahematologic toxicity was observed. Conclusion: This study confirms the safety and high efficacy of 90Y-IT RIT in heavily pretreated FL patients, with the possibility of having a subset of long-term responders.
| Original language | English |
|---|---|
| Pages (from-to) | 258-261 |
| Number of pages | 4 |
| Journal | Clinical Lymphoma, Myeloma and Leukemia |
| Volume | 10 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Aug 2010 |
Fingerprint
Keywords
- Follicular lymphoma
- Non-Hodgkin lymphoma
- Pretreated indolent lymphoma
- Radioimmunotherapy
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Hematology
Cite this
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma : Evaluation of the long-term outcome. / Zinzani, Pier Luigi; Gandolfi, Letizia; Stefoni, Vittorio; Fanti, Stefano; Fina, Mariapaola; Pellegrini, Cinzia; Montini, Gian Carlo; Derenzini, Enrico; Broccoli, Alessandro; Argnani, Lisa; Pileri, Stefano; Baccarani, Michele.
In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 10, No. 4, 08.2010, p. 258-261.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma
T2 - Evaluation of the long-term outcome
AU - Zinzani, Pier Luigi
AU - Gandolfi, Letizia
AU - Stefoni, Vittorio
AU - Fanti, Stefano
AU - Fina, Mariapaola
AU - Pellegrini, Cinzia
AU - Montini, Gian Carlo
AU - Derenzini, Enrico
AU - Broccoli, Alessandro
AU - Argnani, Lisa
AU - Pileri, Stefano
AU - Baccarani, Michele
PY - 2010/8
Y1 - 2010/8
N2 - Background: Based on historical data on the role of radioimmunotherapy (RIT) in pretreated non-Hodgkin lymphoma, we reviewed our hospital's clinical database. Patients and Methods: Between 2005 and 2008, 57 patients previously treated with at least 1 rituximab-containing chemotherapy were treated with Yttrium-90-labeled ibritumomab tiuxetan (90Y-IT). The median number of pretreatments was 3 (range, 1-9 pretreatments). A total of 46 patients had stage III/IV disease (31 with bone marrow involvement); 6 had bulky disease. According to histology, 53 were follicular lymphoma (FL), 2 were marginal zone lymphoma, and 2 were small lymphocytic lymphoma. Results: Overall response rate was 93% (53 of 57); complete response (CR) rate was 70% (40 of 57). Twenty-six of 40 patients (65%) who obtained a CR are in continuous CR (CCR) with a median follow-up of 20 months (range, 10-42 months); 4 of them still maintain their CCR after 36 months. All patients achieving a CCR had FL, and 21 of them with stage III/IV disease; 12 of 26 had been heavily pretreated (≥ 3 previous treatments), and 2 had had autologous stem cell transplantation. Toxicity was primarily hematologic and mostly transient; no grade 4 extrahematologic toxicity was observed. Conclusion: This study confirms the safety and high efficacy of 90Y-IT RIT in heavily pretreated FL patients, with the possibility of having a subset of long-term responders.
AB - Background: Based on historical data on the role of radioimmunotherapy (RIT) in pretreated non-Hodgkin lymphoma, we reviewed our hospital's clinical database. Patients and Methods: Between 2005 and 2008, 57 patients previously treated with at least 1 rituximab-containing chemotherapy were treated with Yttrium-90-labeled ibritumomab tiuxetan (90Y-IT). The median number of pretreatments was 3 (range, 1-9 pretreatments). A total of 46 patients had stage III/IV disease (31 with bone marrow involvement); 6 had bulky disease. According to histology, 53 were follicular lymphoma (FL), 2 were marginal zone lymphoma, and 2 were small lymphocytic lymphoma. Results: Overall response rate was 93% (53 of 57); complete response (CR) rate was 70% (40 of 57). Twenty-six of 40 patients (65%) who obtained a CR are in continuous CR (CCR) with a median follow-up of 20 months (range, 10-42 months); 4 of them still maintain their CCR after 36 months. All patients achieving a CCR had FL, and 21 of them with stage III/IV disease; 12 of 26 had been heavily pretreated (≥ 3 previous treatments), and 2 had had autologous stem cell transplantation. Toxicity was primarily hematologic and mostly transient; no grade 4 extrahematologic toxicity was observed. Conclusion: This study confirms the safety and high efficacy of 90Y-IT RIT in heavily pretreated FL patients, with the possibility of having a subset of long-term responders.
KW - Follicular lymphoma
KW - Non-Hodgkin lymphoma
KW - Pretreated indolent lymphoma
KW - Radioimmunotherapy
UR - http://www.scopus.com/inward/record.url?scp=77957092383&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957092383&partnerID=8YFLogxK
U2 - 10.3816/CLML.2010.n.054
DO - 10.3816/CLML.2010.n.054
M3 - Article
C2 - 20709661
AN - SCOPUS:77957092383
VL - 10
SP - 258
EP - 261
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
SN - 2152-2669
IS - 4
ER -